Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
PreScission Protease: From Tag Cleavage to Mechanism
2026-10-08
PreScission Protease and HRV 3C protease are usually discussed as precision tools for fusion protein tag cleavage. This article examines a broader scientific question: how controlled tag removal can strengthen interpretation of recombinant protein studies involving dKeap1, lamin Dm0, and nuclear architecture.
-
Tamoxifen and CARM1 in Endocrine Models
2026-10-07
Tamoxifen is a selective estrogen receptor modulator whose effects can shape both endocrine-response experiments and conditional genetics. This article examines how tamoxifen should be interpreted alongside new CARM1-targeted evidence, emphasizing mechanistic attribution, model boundaries, and translational relevance.
-
Drug-Sensitized Yeast for mTOR Inhibitor Discovery
2026-10-07
Breen and colleagues developed a drug-sensitized Saccharomyces cerevisiae platform that substantially increases the apparent sensitivity of a yeast growth assay for TOR/mTOR inhibitors. The study identifies known inhibitors and aminophylline while finding no evidence of TOR inhibition for several tested compounds, including nebivolol, within the limits of this model.
-
Partial BACE Inhibition and Synaptic Transmission
2026-10-06
Satir et al. examined whether partial β-secretase inhibition can lower amyloid beta secretion without impairing synaptic transmission. Using cultured rat cortical neurons and optical electrophysiology, the study found that reductions below approximately 50% were not associated with detectable synaptic dysfunction, whereas stronger inhibition reduced both amyloid beta secretion and transmission.
-
Ethacridine Lactate Monohydrate in Chromatin Research
2026-10-06
Ethacridine lactate monohydrate can be examined as a microbial-control variable in advanced chromatin and surface ectoderm studies. This article separates supplier-reported antiseptic properties from the mechanistic evidence in a 2026 YAP–TEAD super-enhancer study.
-
Dhcr7 Knockout Grass Carp and GCRV Resistance
2026-10-05
A 2026 Aquaculture Reports study identified Dhcr7 as an in vivo candidate for GCRV-resistant grass carp breeding. Selected dhcr7 crispants showed approximately 40% higher survival after GCRV-II challenge, stronger antiviral responses, lower viral loads, and less hepatopancreas damage, while growth-related measures were not impaired under the reported study conditions.
-
Aclacinomycin A and Persistent rDNA Stress
2026-10-05
Aclacinomycin A, also known as Aclarubicin, connects topoisomerase-associated DNA damage with apoptosis and proteasome biology. This article interprets its research value through the distinct lens of persistent ribosomal DNA lesions and PML-nucleolar stress responses.
-
How Cholesterol Hinders LNP Intracellular Trafficking
2026-10-04
A 2025 International Journal of Pharmaceutics study developed a streptavidin–biotin-DNA tracking platform to examine how lipid nanoparticle composition shapes intracellular trafficking. Its central finding is that higher cholesterol content promoted peripheral early-endosome accumulation, limiting downstream movement of nucleic acid cargo, while DSPC partially reduced this phenotype.
-
Fulvestrant (ICI 182,780) Workflow Guide
2026-10-02
Build reproducible ER-degradation, MDM2, apoptosis, and chemotherapy-sensitization assays with Fulvestrant. This guide also translates an ER-stress immune study into practical controls while clearly separating validated breast cancer workflows from exploratory cross-domain applications.
-
4-Hydroxytamoxifen (B6167) Workflow Guide
2026-10-01
4-Hydroxytamoxifen (B6167) is an estrogen receptor modulator for controlled DMSO-based workflows in breast cancer research, prostate cancer research, and cardiac myocyte studies. It should not be selected for protocols requiring aqueous or ethanol solubility, and the dossier does not establish a validated dose, schedule, or efficacy protocol.
-
Partial BACE Inhibition and Synaptic Transmission
2026-10-01
Satir et al. examined whether partial β-secretase inhibition can lower amyloid-β secretion without disrupting neuronal communication. Using primary cortical neurons, optical electrophysiology, and three BACE inhibitors, the study identified a functional exposure range in which amyloid beta reduction remained below approximately 50% and synaptic transmission was preserved.
-
DNMT3B and Neuroendocrine Prostate Cancer Plasticity
2026-09-30
The reference study identifies DNMT3B as a driver of therapy-associated neuroendocrine lineage plasticity and stemness in prostate cancer. Genetic and pharmacologic experiments indicate that suppressing DNMT3B reduces neuroendocrine prostate cancer growth, alters differentiation programs, and promotes apoptosis, providing a rationale for further translational investigation.
-
Fulvestrant (ICI 182,780) ER Research Guide
2026-09-30
Explore how Fulvestrant (ICI 182,780) supports ERα degradation studies, MDM2 protein degradation research, and chemotherapy-sensitization workflows. This guide also shows how to adapt the compound as a mechanistic control in estrogen–immune signaling assays while avoiding unsupported cross-domain conclusions.
-
Multiomics of Crossbreeding and Goose Meat Quality
2026-09-29
The reference study combined RNA-seq and nontargeted metabolomics to examine how crossbreeding and sex shape growth, carcass traits, and meat quality in Xingguo gray geese. Its integrated analysis connected production phenotypes with muscle-development and lipid-metabolism signals, providing a molecular framework for interpreting crossbred performance beyond conventional carcass measurements.
-
Foretinib (GSK1363089) Research Workflows
2026-09-29
Build stronger Foretinib assays by separating tumor cell growth inhibition from true cell killing and by pairing proliferation, motility, invasion, and metastasis endpoints. This workflow combines dose-controlled in vitro experiments with translational guidance for cancer metastasis models and ovarian cancer xenograft studies.